In our meta-analysis, we included 5 randomized clinical trials to evaluate the efficacy and safety of anti-PD-1/PD-L1 antibody therapy compared with docetaxel in previously treated advanced NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.